Paper36484103
m6 A Reader YTHDF1-Targeting Engineered Small Extracellular Vesicles for Gastric Cancer Therapy via Epigenetic and Immune Regulation.
You Q and 10 others. Adv Mater, 2023. Cited by 88 papers, by iCite.
Cite this record
ConductScience Library. m6 A Reader YTHDF1-Targeting Engineered Small Extracellular Vesicles for Gastric Cancer Therapy via Epigenetic and Immune Regulation. Papers, record 36484103. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36484103
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- m6 A Reader YTHDF1-Targeting Engineered Small Extracellular Vesicles for Gastric Cancer Therapy via Epigenetic and Immune Regulation.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Stomach Neoplasms | Major topic |
| Extracellular Vesicles | Major topic |
| Humans | |
| CD47 Antigen | |
| Immunotherapy | |
| Epigenesis, Genetic | |
| RNA-Binding Proteins |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 31971295 | National Natural Science Foundation of China | PubMed | ||
| 2021YFA1201500 | National Key Research and Development Program of China | PubMed | ||
| XDB36000000 | The Strategic Priority Research Program of Chinese Academy of Science | PubMed |
Source PubMed
Cited by63
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 88 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42756925 | m6A-Targeted Cancer Therapy: Molecular Targets, Inhibitors, and Nanodelivery Strategies. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42756925 | PubMed |
| 42534149 | m6A methylation regulatory network in pulmonary fibrosis: Molecular mechanisms from RNA stability to cellular phenotype transition (Review). | Exp Ther Med | 2026 | https://conductscience.org/library/papers/42534149 | PubMed |
| 42427965 | Advancements in extracellular vesicle research. | Extracell Vesicle | 2026 | https://conductscience.org/library/papers/42427965 | PubMed |
| 42164998 | Hit the bull's eye: Engineered extracellular vesicles for targeted therapy. | Bioact Mater | 2026 | https://conductscience.org/library/papers/42164998 | PubMed |
| 42077735 | Global Research Trends in Gastric Cancer Epigenetics From 2005 to 2025. | Cureus | 2026 | https://conductscience.org/library/papers/42077735 | PubMed |
| 42072692 | Unravelling Multilayered RNA Modification Networks in Female Reproduction and Obstetric/Gynaecologic Disorders. | Biomolecules | 2026 | https://conductscience.org/library/papers/42072692 | PubMed |
| 42056258 | YTHDF1/SLC39A4 signaling axis promotes gastric cancer cell proliferation by suppressing cuproptosis ex vivo and in vitro. | Cancer Gene Ther | 2026 | https://conductscience.org/library/papers/42056258 | PubMed |
| 41992985 | RNA‑binding proteins as epithelial transcriptome orchestrators in gastric cancer: Immune‑metabolic crosstalk and therapeutic vulnerability (Review). | Int J Mol Med | 2026 | https://conductscience.org/library/papers/41992985 | PubMed |
| 41904346 | The m6A-circRNA axis: a therapeutic prospect for gastric cancer. | Cell Biol Toxicol | 2026 | https://conductscience.org/library/papers/41904346 | PubMed |
| 41832397 | RNA m6A modification is a driver and therapeutic target in gastric cancer. | Cell Biol Toxicol | 2026 | https://conductscience.org/library/papers/41832397 | PubMed |
| 41809263 | Extracellular vesicles in cancer immunotherapy: Therapeutic, challenges and clinical progress. | Asian J Pharm Sci | 2025 | https://conductscience.org/library/papers/41809263 | PubMed |
| 41629530 | RBM15B recognizes H3K79me2 to guide selective m6A-modification of mRNA and enhance oncoprotein translation in MLL-r leukemia. | EMBO J | 2026 | https://conductscience.org/library/papers/41629530 | PubMed |
| 41607610 | The epitranscriptome meets non-coding RNA: m6A-mediated regulation in oncogenesis and therapy. | Front Cell Dev Biol | 2025 | https://conductscience.org/library/papers/41607610 | PubMed |
| 41597006 | Untargeted Metabolomics Reveals Raw Material Geographic Origin as a Key Factor Shaping the Quality of Ginger-Derived Exosome-like Nanovesicles. | Foods | 2026 | https://conductscience.org/library/papers/41597006 | PubMed |
| 41522350 | Targeting the HSP60/p53 Axis with Extracellular Vesicle-Delivered siRNA Reprograms Glycolysis in Prostate Cancer. | Int J Biol Sci | 2026 | https://conductscience.org/library/papers/41522350 | PubMed |
| 41457218 | RNA modifications: roles in immune cell biology and tumor regulation. | Cancer Cell Int | 2025 | https://conductscience.org/library/papers/41457218 | PubMed |
| 41423606 | The crosstalk of m6A modification and non-coding RNAs in gastric cancer: biomarkers and therapeutic potentials. | Cancer Cell Int | 2025 | https://conductscience.org/library/papers/41423606 | PubMed |
| 41404378 | Advancing Epigenetic Combination Therapy in Oncology: Multifunctional Nano-Drug Delivery Systems for Synergistic Efficacy and Precision Modulation. | Int J Nanomedicine | 2025 | https://conductscience.org/library/papers/41404378 | PubMed |
| 41022614 | [Therapeutic potential of extracellular vesicles in neurological diseases]. | Nan Fang Yi Ke Da Xue Xue Bao | 2025 | https://conductscience.org/library/papers/41022614 | PubMed |
| 40958857 | Interactions between ALKBH5 and reader proteins in tumors: functions and molecular mechanisms. | Front Oncol | 2025 | https://conductscience.org/library/papers/40958857 | PubMed |
Genes8
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD47 | 961 | PubTator's text mining | https://conductscience.org/library/genes/961 | NCBI Gene |
| CTNNB1 | 1499 | PubTator's text mining | https://conductscience.org/library/genes/1499 | NCBI Gene |
| FZD7 | 8324 | PubTator's text mining | https://conductscience.org/library/genes/8324 | NCBI Gene |
| GPM6A | 2823 | PubTator's text mining | https://conductscience.org/library/genes/2823 | NCBI Gene |
| IFNG | 3458 | PubTator's text mining | https://conductscience.org/library/genes/3458 | NCBI Gene |
| IFNGR1 | 3459 | PubTator's text mining | https://conductscience.org/library/genes/3459 | NCBI Gene |
| SIRPA | 140885 | PubTator's text mining | https://conductscience.org/library/genes/140885 | NCBI Gene |
| YTHDF1 | 54915 | PubTator's text mining | https://conductscience.org/library/genes/54915 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36484103
GET https://conductscience.org/api/papers/v1/36484103/cited_by?page=2